Recommendations for management of iron overload in MDS patients
| Characteristic . | NCCN92 . | MDS Foundation91 . |
|---|---|---|
| Transfusion status | Received >20 RBC transfusions; continuing transfusions | Transfusion dependent, requiring 2 U/mo for >1 y |
| Serum ferritin concentration | >2500 μg/L | >1000 μg/L |
| MDS risk category | IPSS: low or intermediate-1 | IPSS: low or intermediate-1; WHO: RA, RARS, and 5q− |
| Patient profile | Candidate for allograft | Candidate for allograft; need to preserve organ function; life expectancy >1 y without comorbidities limiting progress |
| Characteristic . | NCCN92 . | MDS Foundation91 . |
|---|---|---|
| Transfusion status | Received >20 RBC transfusions; continuing transfusions | Transfusion dependent, requiring 2 U/mo for >1 y |
| Serum ferritin concentration | >2500 μg/L | >1000 μg/L |
| MDS risk category | IPSS: low or intermediate-1 | IPSS: low or intermediate-1; WHO: RA, RARS, and 5q− |
| Patient profile | Candidate for allograft | Candidate for allograft; need to preserve organ function; life expectancy >1 y without comorbidities limiting progress |
IPSS, International Prognostic Scoring System.